Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | C5 | P01031 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22769588 | 0.92 | HDAC1 (0.54) | PTGS1HDAC2HDAC6HDAC8HDAC1 | |
| SCHEMBL22769599 | 0.86 | PTGS1 (0.50) | PTGS1HDAC2HDAC6HDAC8HDAC1 | |
| SCHEMBL5774112 | 0.85 | RXRA (0.56) | PTGS1NR4A2FFAR4KDM4EABCC4 | |
| SCHEMBL2279660 | 0.76 | NR4A2 (0.54) | PTGS1NR4A2FFAR4KDM4EABCC4 | |
| SCHEMBL5773088 | 0.75 | MAPT (0.45) | PTGS1HDAC2HDAC6HDAC1NR4A2 | |
| SCHEMBL5773092 | 0.74 | PTGS1 (0.42) | PTGS1HDAC2HDAC6HDAC1FFAR4 | |
| SCHEMBL31526337 | 0.74 | PTGS1 (0.47) | PTGS1FFAR4PTGS2ALDH1A1 | |
| SCHEMBL12406914 | 0.73 | PTGS1 (0.59) | PTGS1NR4A2FFAR4KDM4ELMNA | |
| SCHEMBL22769603 | 0.72 | HDAC2 (0.47) | HDAC2HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL5729762 | 0.71 | NR4A2 (0.45) | PTGS1NR4A2FFAR4KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388544-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | VIVORYON THERAPEUTICS N.V. (DE) | 2025-12-25 | — | — | US | disclosed |
| EP-3750878-B1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | VIVORYON THERAPEUTICS N V (DE) | 2025-05-14 | — | — | EP | disclosed |
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | VIVORYON THERAPEUTICS N.V. (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | VIVORYON THERAPEUTICS N.V. (DE) | 2023-04-20 | — | — | US | disclosed |
| CN-114585608-A | Heteroaromatic inhibitors of astacin protease | 维沃永治疗公众有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3986868-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | Vivoryon Therapeutics N.V. (DE) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020249760-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | VIVORYON THERAPEUTICS AG (DE) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249760-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | VIVORYON THERAPEUTICS AG (DE) | 2020-12-17 | — | — | WO | disclosed |
| EP-3750878-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | Vivoryon Therapeutics AG (DE) | 2020-12-16 | — | — | EP | disclosed |
| EP-3750878-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | Vivoryon Therapeutics AG (DE) | 2020-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | BMP1, DPEP1, MEP1A | PTGS1 426/4885HDAC2 2265/4885HDAC6 2611/4885 |
| US-20250388544-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | BMP1, BMPR1A, BMPR1B | PTGS1 595/4885HDAC2 2963/4885HDAC6 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.